abt-436
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2009 (NCT01050127)
Timeline
Indications
Mechanism of action
- Vasopressin V1b receptorINHIBITOR
AVPR1B inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- abt-436
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01613014 | Phase 2 | Feb 1, 2013 | AbbVie, National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT01741142 | Phase 2 | Jan 1, 2012 | AbbVie |
| NCT01380704 | Phase 1 | Jun 1, 2011 | Abbott |
| NCT01050127 | Phase 1 | Dec 1, 2009 | Abbott |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbott | For profit | 2 | 2 | 1 | 2009 |
| AbbVie | For profit | 2 | 1 | 1 | 2012 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 1 | 1 | 2013 |
3 organizations
Page 1 / 1